| 1 |
1405/5/1 |
Semaglutide in Modern Endocrinology From Glycemic Control to Multiorgan Protection
|
| 2 |
1405/3/21 |
سیتولوژی ندولهای تیروئید (AUS) |
| 3 |
1405/05/29 |
Combination treatment for the management of chronic kidney |
| 4 |
1405/05/15 |
هایپرتیروئید در بارداری |
| 5 |
1405/05/08 |
تیروئید در بارداری |
| 6 |
1405/04/18 |
Precision_Pituitary_Radiosurgery |
| 7 |
1405/04/11 |
تشخیص بیماری کبد چرب و آشنایی با داروی Resmetirom |
| 8 |
1405/02/31 |
کاربرد بالینی و مدیریت عوارض دارویی Tirzepatide |
| 9 |
1405/02/24 |
hypercalcemia of malig |
| 10 |
1405/02/17 |
Neuropathy, and Foot Care: Standards of Care in Diabetes—2026 |
| 11 |
1404/7/3 |
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer |
| 12 |
1404/2/18 |
The Porphyrias Disorders of Heme Synthesis |
| 13 |
1404/2/11 |
Guideline for the Prevention and Treatment |
| 14 |
1404/11/9 |
Case Presention |
| 15 |
1404/11/30 |
Transition from childhood to adulthood in classic CAH |
| 16 |
1404/11/23 |
درمان دارویی چاقی |
| 17 |
1404/11/2 |
prolactinoma |
| 18 |
1404/11/16 |
Revised European Society of Endocrinology Clinical Practice Guideline |
| 19 |
1404/10/4 |
management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|
| 20 |
1404/10/25 |
Finerinone
from clinical needs to clinical application |
| 21 |
1404/10/18 |
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline |
| 22 |
1404/10/11 |
Standards of Care in Diabetes-2026 |
| 23 |
1404/1/28 |
HYPERTHYROHDISM |
| 24 |
1404/1/21 |
Rdioactive Lodin Therapy |
| 25 |
1404/09/27 |
Management of parathyroid disorders |
| 26 |
1404/09/20 |
Evaluation and management of menopause and the perimenopause |
| 27 |
1404/09/13 |
Sarcopenia in Patients with Type 2 Diabetes Mellitus |
| 28 |
1404/08/29 |
European Society of Endocrinology and Endocrine Society Joint Clinical Guideline
|
| 29 |
1404/07/24 |
ATA-2025 |
| 30 |
1404/07/17 |
ATA Management Guidelines 2025 for Adult Patients with Differentiated Thyroid |
| 31 |
1404/07/10 |
American Thyroid Association Management Guidelines 2025 for Adult Patients with Differentiated Thyroid Cancer |
| 32 |
1403/12/9 |
Onset and progression of osteoporosis |
| 33 |
1403/12/23 |
Diabetes insipidus |
| 34 |
1403/12/2 |
screening or not screening T1D ISPAD 2024 Recommendations |
| 35 |
1403/12/16 |
Ramadan and Diabetes |
| 36 |
1403/11/25 |
Insulin Resistance and Diabetes Mellitus |
| 37 |
1403/11/18 |
Adrenal cortical carcinoma |
| 38 |
1403/11/11 |
Management of diabetic foot ulcers |
| 39 |
1403/10/27 |
DIABETES AND CANCER |
| 40 |
1403/10/20 |
Management of challenging and complicated patients with DM |
| 41 |
1403/10/13 |
Dyslipidemia management in pregnant patients: a 2024 update |
| 42 |
1403/10/06 |
Adrenal insufficiency:identification and management |
| 43 |
1403/09/29 |
Pheochromocytoma and paraganglioma in children |
| 44 |
1403/09/01 |
How to manage Cushing’s disease after failed primary pituitary surgery |
| 45 |
1403/08/24 |
Surgery of the Adrenal Glands |
| 46 |
1403/08/24 |
Surgical Approaches to the Adrenal Gland |
| 47 |
1403/08/17 |
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows |
| 48 |
1403/08/10 |
Acromegaly |
| 49 |
1403/08/03 |
BEMPEDOIC ACID, DEVELOPMENT AND CLINICAL APPLICATION |
| 50 |
1403/07/26 |
postmenopausal osteoporosis |
| 51 |
1403/07/19 |
Salivary Cortisol test |
| 52 |
1403/07/19 |
Late night salivary cortisol |
| 53 |
1403/07/12 |
CKD-MBD |
| 54 |
1403/07/05 |
Clinical Indication of FDG PET-CT in DTC |
| 55 |
1403/04/14 |
The Genetic Testing in Endocrine Disorders |
| 56 |
1403/03/31 |
Cyclic Cushing’s Disease |
| 57 |
1403/03/20 |
Primary Aldosteronism Novel Approaches and Future Outlooks |
| 58 |
1403/03/17 |
Diabetic Nephropathy |
| 59 |
1403/03/10 |
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer |
| 60 |
1403/03/03 |
2023 European Thyroid Association Clinical Practice Guidelines for Thyroid nodule management |
| 61 |
1403/02/27 |
Bariatric Surgery |
| 62 |
1403/02/13 |
Abnormal uterine bleeding in adolescents: Management |
| 63 |
1403/02/06 |
Multimodality imaging of primary hyperparthyroidism |
| 64 |
1403/01/30 |
Perioperative Evaluation and Management of Patients on Glucocorticoids |
| 65 |
1403/01/16 |
Review of ICE 2024 |
| 66 |
1402/12/24 |
Management of Advanced Thyroid Cancer: Overview, Advances, and Opportunities |
| 67 |
1402/12/17 |
Medical Nutrition Therapy IN Diabetes |
| 68 |
1402/12/10 |
Diabetic Bladder or Diabetic Cystopathy &related complicationc |
| 69 |
1402/12/03 |
The Revolution in Cholesterol Management: Putting REPATHA into practice
|
| 70 |
1402/11/26 |
EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma
|
| 71 |
1402/11/12 |
Glucocorticoidinduced osteoporosis (GIOP)
|
| 72 |
1402/10/28 |
Thyroid Scintigraphy
|
| 73 |
1402/10/21 |
MTC
|
| 74 |
1402/10/14 |
Summary of Revisions: Standards of Medical Care in Diabetes—2024
|
| 75 |
1402/10/07 |
Summary of Revisions: Standards of Medical Care in Diabetes—2024
|
| 76 |
1402/09/30 |
OBESITY MANAGEMENT IN ADULTS
|
| 77 |
1402/09/23 |
Prolactinomas |
| 78 |
1402/09/16 |
Updates on Thyroid eye disease
|
| 79 |
1402/09/09 |
Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines
|
| 80 |
1402/08/25 |
Nuclear Medicine In Diabetic Foot
|
| 81 |
1402/08/18 |
Syndrome of Inappropriate Antidiuresis
|
| 82 |
1402/08/11 |
Hypothyroidism
|
| 83 |
1402/08/04 |
Management of Osteoporosis in Postmenopausal Woman
|
| 84 |
1402/07/27 |
EVALUATION & MANAGEMENT OF INFANT WITH DSD |
| 85 |
1402/07/21 |
PCOS GUIDLINE 2023
|
| 86 |
1402/07/13 |
Adrenal Incidentaloma
|
| 87 |
1402/07/06 |
Acromegaly original
|
| 88 |
1401/08/10 |
Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers
|
| 89 |
1400/04/04
|
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
|
| 90 |
1400/03/28
|
Type 1 Diabetes: Management in Women From Preconception to Postpartum
|
| 91 |
1400/03/21
|
American Association of Clinical Endocrinology And Associazione Medici Endocrinologi Thyroid Nodule Algorithmic Tool
|
| 92 |
1400/03/07
|
Vitamin D Update
|
| 93 |
1400/02/31
|
Active Surveillance of Adult Low-Risk Papillary Thyroid Carcinoma
|
| 94 |
1400/02/17
|
Management of Hypertriglyceridemia
|
| 95 |
1400/02/10
|
Adrenal Incidentaloma
|
| 96 |
1400/02/03
|
Diagnosis and Treatment of NCCAH due to 21-Hydroxylase Deficiency
|
| 97 |
1400/01/27
|
New Oral Options for Diabetic Dyslipidemia Managment
|
| 98 |
1400/01/20
|
Testosterone Deficiency in Men
|
| 99 |
1399/12/22
|
The Evolution of the Primary Aldosteronism Syndrome: Updating the Approach
|
| 100 |
1399/12/15
|
Role of Nuclear Medicine in Endocrinology
|
| 101 |
1399/12/08
|
Pituitary Disorders in Pregnancy
|
| 102 |
1399/12/01
|
IDF DaR Guideline for people with diabetes who want to fast in Ramadan
|
| 103 |
1399/11/24
|
Thyroid Eye Disease: Managing a Condition with Grave Consequences
|
| 104 |
1399/11/17
|
Dyslipidemia in Children
|
| 105 |
1399/11/10
|
Clinical Indication of FDG PET-CT in DTC
|
| 106 |
1399/11/03
|
Pediatric Type 2 Diabetes: Not a Mini Version of Adult Type 2 Diabetes
|
| 107 |
1399/10/26
|
Practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours (NET)
|
| 108 |
1399/10/19
|
Lipid Management in Patients with Endocrine Disorders
|
| 109 |
1399/10/12
|
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices
|
| 110 |
1399/10/05
|
ADA 2021 Review
|
| 111 |
1399/09/28
|
Management of Graves‘ Thyroidal and Extrathyroidal Disease – An Update
|
| 112 |
1399/09/21
|
Approach to Managing a Postmenopausal Patient
|
| 113 |
1399/09/14
|
Endocrine Surgery during the Covid-19 pandemic
|
| 114 |
1399/09/07
|
Turner Syndrome Genome
|
| 115 |
1399/08/30
|
Glucocorticoid-Induced Osteoporosis
|
| 116 |
1399/08/09
|
Pituitary Incidentalomas
|
| 117 |
1399/08/02
|
How to use TBS in combination with BMD in clinical practice
|
| 118 |
1399/07/25
|
Glucocorticoid Induce Hyperglycemia
|
| 119 |
1399/07/18
|
Hypoparathyroidism
|
| 120 |
1399/07/11
|
Normocalcaemic Primary Hyerparathyroidism
Normocalcaemic PHP
|
| 121 |
1399/07/04
|
GLP-1 AGONISTS vs SGLT2-inh ECE 2020
|
| 122 |
1399/03/27
|
PDE5 Inhibitors in Type 2 Diabetes Mellitus
|
| 123 |
1399/03/20
|
Dietary Fats and Health Outcome
|
| 124 |
1399/03/13
|
Medical Treatment with Somatostatin Analogues & Predictive Markers for Post-Surgical Medical Management of Acromegaly
|
| 125 |
1399/03/06
|
Pituitary-Tumor Endocrinopathies
|
| 126 |
1399/02/30
|
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline
|
| 127 |
1399/02/23
|
Osteoporosis in Men
|
| 128 |
1399/02/16
|
PCOS in Adolescents
|
| 129 |
1399/02/09
|
Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline
|
| 130 |
1399/02/02
|
Diabetes & Ramadan Fasting - 2020
|
| 131 |
1399/01/26
|
COVID-19 and Endocrine System
|
| 132 |
1399/01/20
|
European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity
|
| 133 |
1398/11/29
|
Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline
|
| 134 |
1398/11/15
|
Prolactinoma in Pregnancy and Menopause
|
| 135 |
1398/11/08
|
Nuclear Medicine & Parathyroid Diseases
|
| 136 |
1398/11/01
|
Management of Hypopituitarism
|
| 137 |
1398/10/24
|
Thermal Ablation for Papillary Thyroid Microcarcinomas
|
| 138 |
1398/10/17
|
ADA 2020 - Standards of Medical Care in diabetes
|
| 139 |
1398/10/10
|
2019European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer
|
| 140 |
1398/10/03
|
Hypogonadism in Men
|
| 141 |
1398/09/26
|
Prolactinoma in Pregnancy
|
| 142 |
1398/09/19
|
Familial hypercholesterolemia in children “Diagnosis and Treatment “
|
| 143 |
1398/09/12
|
Contemporary Debates in Adult Papillary Thyroid Cancer Management
|
| 144 |
1398/09/05
|
Management Of Graves Orbitopathy
|
| 145 |
1398/08/28
|
Management of Difficult Osteoporosis
|
| 146 |
1398/08/21
|
Medical Management of Cushing’s Syndrome
|
| 147 |
1398/08/14
|
Prolactinoma
|
| 148 |
1398/07/30
|
Adrenal Crisis
|
| 149 |
1398/07/23
|
Drug Effects on the Thyroid
|
| 150 |
1398/07/16
|
Lipid
|
| 151 |
1398/07/09
|
Pheochromocytoma and Paraganglioma
|
| 152 |
1398/07/02
|
AROMATASE INHIBITORS AND BONE - ECE 2019
|
| 153 |
1398/03/28
|
Endocrine Treatment of Gender - Dysphoric/Transsexual Person
|
| 154 |
1398/03/21
|
Principles of DXA Scan Interpretation
|
| 155 |
1398/03/07
|
The Indeterminate Thyroid Nodule
|
| 156 |
1398/02/31
|
Prevention of Type 1 Diabetes
|
| 157 |
1398/02/24
|
Management of Medullary Thyroid Cancer
|
| 158 |
1398/02/17
|
Adrenal Imaging
|
| 159 |
1398/02/10
|
Osteoprosis Recumendations
|
| 160 |
1398/02/03
|
The Evaluation of Incidentally Discovered Adrenal Masses
|
| 161 |
1398/01/27
|
Update on Central Precocious Puberty: From Etiologies to Outcomes
|
| 162 |
1398/01/20
|
Treatment of Diabetes in Older Adults
|
| 163 |
1397/12/21
|
Diabetes Technology: Standards of Medical Care in Diabetes 2019
|
| 164 |
1397/12/14
|
The Management of Primary Aldosteronism Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline
|
| 165 |
1397/12/07
|
Sglt2 Inhibitor
|
| 166 |
1397/11/30
|
Controversial issues in the management of hyperprolactinemia and prolactinomas – An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism
|
| 167 |
1397/11/23
|
BMD
|
| 168 |
1397/11/16
|
Thyroid and Pregnancy
|
| 169 |
1397/11/09
|
Long-term Safety & Efficacy of GH Treatment
|
| 170 |
1397/11/02
|
Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study
|
| 171 |
1397/10/25
|
The Diagnosis and Management of Nonalcoholic Fatty Liver Disease
|
| 172 |
1397/10/18
|
Gaps in Guidelines for the Management of Diabetes in Low and Middle-Income Versus High-Income Countries: A Systematic Review
|
| 173 |
1397/10/11
|
RAI in low risk DTC
|
| 174 |
1397/10/04
|
Management of Hyperglycemia in Type 2 Diabetes, 2018
|
| 175 |
1397/09/27
|
Diabetic Neuropathy
|
| 176 |
1397/09/20
|
OSTEOGENESIS IMPERFECTA
|
| 177 |
1397/09/13
|
Conventional & New Treatments of Hypoparathyroidism
|
| 178 |
1397/09/06
|
CONGENITAL ADRENAL HYPERPLASIA
|
| 179 |
1397/08/29
|
ORAL SEMAGLUTIDE vs PLACEBO
|
| 180 |
1397/08/15
|
ACROMEGALY
|
| 181 |
1397/08/01
|
2018European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction
|
| 182 |
1397/07/24
|
Adrenocortical Carcinoma
|
| 183 |
1397/07/17
|
Gestational Diabetes Underpinning Principles, Surveillance, and Management
|
| 184 |
1397/07/10
|
2018European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
|
| 185 |
1397/07/03
|
Recommendations from the International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome
|
| 186 |
1397/03/29
|
Charcot Foot
|
| 187 |
1397/03/22
|
X-linked Hypophosphatemic Rickets and its Treatment with Anti-FGF23
|
| 188 |
1397/03/08
|
Differentiated Thyroid Cancer Subtypes and Prognosis
|
| 189 |
1397/03/01
|
Incidence of Bone Metastases in Differentiated Thyroid Cancer
|
| 190 |
1397/02/25
|
Ramadan Fasting & Health
|
| 191 |
1397/02/18
|
Testosterone Therapy in Men With Hypogonadism
|
| 192 |
1397/02/11
|
Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans
|
| 193 |
1397/01/28
|
Acromegaly: An Endocrine Society Clinical Practice Guideline
|
| 194 |
1397/01/21
|
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
|
| 195 |
1397/01/14
|
Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline
|
| 196 |
1396/12/22
|
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Managment Algorithm-2018 Executive Summary
|
| 197 |
1396/12/15
|
2017Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum
|
| 198 |
1396/12/08
|
Some Points & Recommendations for Diagnosis Growth Hormone Deficiency in Children and Adolescents
|
| 199 |
1396/11/24
|
Definition of Pheochromocytomaand Paraganglioma (PPGL)
|
| 200 |
1396/11/17
|
Magnetic Resonance Imaging of Pituitary Tumors
|
| 201 |
1396/11/10
|
Diagnosis and Treatment PCOS
|
| 202 |
1396/11/03
|
Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline
|
| 203 |
1396/10/26
|
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, revention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
|
| 204 |
1396/10/19
|
Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents
|
| 205 |
1396/10/12
|
Clinically Nonfunctioning Pituitary Adenomas
|
| 206 |
1396/10/05
|
Standards of Medical Care in Diabetes - 2018
|
| 207 |
1396/09/28
|
AACE FOR MANAGEMENT OF DYSLIPIDEMIA
|
| 208 |
1396/09/14
|
Pituitary Apoplexy
|
| 209 |
1396/09/07
|
Non-Classic Congenital Adrenal Hyperplasia
|
| 210 |
1396/08/30
|
Nuclear Medicine in Neuroendocrine Tumors
|
| 211 |
1396/08/23
|
Type 2 Diabetes and Osteoporosis
|
| 212 |
1396/08/16
|
The Management of Primary Aldosteronism
|
| 213 |
1396/08/09
|
Prolactinoma
|
| 214 |
1396/08/02
|
PERIPHERAL PRECOCITY
|
| 215 |
1396/07/25
|
The follicular-variant papillary thyroid cancer (FVPTC)
|
| 216 |
1396/07/18
|
Gestational Diabetes Mellitus
|
| 217 |
1396/07/11
|
Approach to the Patient with Progressive Radioiodine-Refractory Thyroid Cancer - When to Use Systemic Therapy
|
| 218 |
1396/07/04
|
Management of Graves Orbitopathy ECE2017
|
| 219 |
1396/03/30
|
Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline
|
| 220 |
1396/03/23
|
Pathogenesis and management of hypoglycemia
|
| 221 |
1396/03/16
|
Diabetes and Ramadan
|
| 222 |
1396/03/09
|
Combination Therapy in DM2
|
| 223 |
1396/03/02
|
Gastrointestinal Manifestations of Diabetes
|
| 224 |
1396/02/26
|
Ovarian Hyperthecosis
|
| 225 |
1396/02/19
|
Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study
|
| 226 |
1396/02/12
|
An update on sodium-glucose co transporter-2 inhibitors for the treatment of diabetes mellitus
|
| 227 |
1396/01/15
|
Physiological and molecular responses to bariatric
|
| 228 |
1395/12/17
|
Physical activity and exercise in children with diabetes mellitus type 1
|
| 229 |
1395/12/10
|
Pseudohypoparathyroidism, Albright’s Hereditary Osteodystrophy-Disorders Caused by Inactivating GNAS Mutations
|
| 230 |
1395/11/26
|
Management of Osteoporosis
|
| 231 |
1395/11/19
|
2017Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum
|
| 232 |
1395/11/12
|
2017Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum
|
| 233 |
1395/11/07
|
Effect of Somatostatin Analogs on the Cardiovascular System in Acromegaly
|
| 234 |
|
Primary Male Hypogonadism and Testosterone Therapy
|
| 235 |
|
Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline
|
| 236 |
|
Timing of multiple endocrine neoplasia thyroidectomy and extent of central nacklymphadenectomy
|
| 237 |
|
Hyperglycemia Management In Patients With Post Transplantation Diabetes
|
| 238 |
|
2015American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer
|
| 239 |
|
Premature Ovarian Failure Clinical Presentation and Treatment
|
| 240 |
|
Clinical Practice Guidlines for the Diagnosis and Treatment of Postmenopausal Osteoprosis (2016)
|
| 241 |
|
Premature adrenarche
|
| 242 |
|
Diabetic Sensory and Motor Neuropathy
|
| 243 |
|
Update on subclinical thyroid dysfunction
|
| 244 |
|
Thyroid lymphoma
|
| 245 |
|
Glinids & Metformin
|
| 246 |
|
2016American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and other causes of Thyrotoxicosis
|
| 247 |
|
Pharmacotherapy for obesity and type 2 diabetes
|
| 248 |
|
Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR<45 <span data-scayt_word="mL" data-scaytid="146">mL/min) - Dr.Karimifard
|
| 249 |
|
Postsurgical hypoparathyroidism definitions and management
|
| 250 |
|
Standards of Medical Care in Diabetes — 2016
|
| 251 |
|
Thiazolidinediones Alpha and Glucosidase Inhibitors
|
| 252 |
|
Effect of Somatostatin Analogs on the Cardiovascular System in Acromegaly: A Metaanalysis
|
| 253 |
|
2016American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and other causes of Thyrotoxicosis part 2
|
| 254 |
|
Alcohol Ablation It’s indication, Efficacy, and Safety in Thyroid Disease
|
| 255 |
|
Central precocious puberty
|
| 256 |
|
Postoperative Management Following Pituitary Surgery
|
| 257 |
|
Diabetes and Ramadan: Practical Guidelines
|
| 258 |
|
The Increasing Incidence of Thyroid Cancer
|
| 259 |
|
EASD (2016)
|
| 260 |
|
2015American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules
|
| 261 |
|
Achieving and Maintaining Weight Loss in Obesity: Clinical Evidence for Novel Approaches
|
| 262 |
|
European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for phaeochromocytomaor a paraganglioma
|
| 263 |
|
Approach to diabetes mellitus in children and Adolescents
|
| 264 |
|
Postmenopausal Osteoporosis
|
| 265 |
|
Diagnostic tests of cushing syndrome
|
| 266 |
|
RED CELL TRANSFUSION
|
| 267 |
|
DPP-4 inhibitors
|
| 268 |
|
2015American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer
|
| 269 |
|
Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
|
| 270 |
|
Limitation of current approaches for the treatment of acromegaly
|
| 271 |
|
COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM
|
| 272 |
|
Primary ovarian insufficiency (POI)
|
| 273 |
|
Comprehensive Type 2 Diabetes Managment Algorithm (part 2)
|
